Provided by Tiger Trade Technology Pte. Ltd.

Lantern Pharma Inc.

2.34
+0.05002.18%
Post-market: 2.380.0400+1.71%19:30 EDT
Volume:185.08K
Turnover:427.98K
Market Cap:29.86M
PE:-1.43
High:2.41
Open:2.32
Low:2.13
Close:2.29
52wk High:4.70
52wk Low:1.11
Shares:12.76M
Float Shares:10.14M
Volume Ratio:1.23
T/O Rate:1.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6362
EPS(LYR):-1.5709
ROE:-400.92%
ROA:-74.29%
PB:-9.28
PE(LYR):-1.49

Loading ...

Lantern Pharma Directors Make Bold Insider Moves That Investors Can’t Ignore

TIPRANKS
·
May 15

Lantern Pharma raises capital, plans AI platform spinoff

TIPRANKS
·
May 15

Lantern Pharma director Lee T. Schalop acquires 48,544 shares for $99,999.64

Reuters
·
May 15

Lantern Pharma Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
May 14

Lantern Pharma prices 2.14M shares at $2.06 in registered direct offering

TIPRANKS
·
May 14

Lantern Pharma issues unregistered warrants in private placement for 2,135,923 shares

Reuters
·
May 13

Lantern Pharma prices registered direct offering at $2.06 per share, raises $4.4 million

Reuters
·
May 13

Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering With Existing Holders and a Single Institutional Investor

THOMSON REUTERS
·
May 13

Press Release: Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026

Dow Jones
·
May 12

Lantern Pharma schedules first-quarter results update

Reuters
·
May 12

Lantern Pharma Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
May 11

Lantern Pharma unveils roadmap for withZeta.ai

TIPRANKS
·
May 08

Lantern Pharma plans ZetaSwarm, ZetaOmics additions to withZeta.ai in coming year

Reuters
·
May 07

Lantern Pharma announces expansion of predictBBB.ai into LQM

TIPRANKS
·
Apr 29

Lantern Pharma expands predictBBB.ai into real-time small-molecule quantitative model web service

Reuters
·
Apr 29

Lantern Pharma to host live public demo of withZeta.ai platform in two sessions

Reuters
·
Apr 24

Lantern Pharma schedules Type C meeting with FDA for Phase 2 HARMONIC trial

TIPRANKS
·
Apr 20

BRIEF-Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments

Reuters
·
Apr 20

Lantern Pharma Inc - Lp-300 Demonstrates 8.3-Month Median Progression-Free Survival With No Added Toxicity

THOMSON REUTERS
·
Apr 20

Lantern Pharma reports LP-300 shows 8.3-month median PFS in EGFR L858R NSCLC trial

Reuters
·
Apr 20